Goals and Activities:
Acquire conventional and novel biomarkers in biofluid (CSF, blood), brain images (PET, MRI), and other modalities (e.g., retinal imaging) in adjudicated participant groups.
- Analyze biomarkers to obtain standardized measures and support relevant funded Alzheimer’s disease (AD) research projects affiliated with the ADRC.
- Provide resources integrating multi-dimensional biomarkers data across all human subjects to assist and train ADRC researchers to investigate the underlying age-related drivers for AD.
- Disseminate our expertise and knowledge to support the AD community at large.
- Assays currently being run on ADRC samples (or available at DMPI to run on ADRC samples): CSF abeta40 and 42, tau & p-tau-181p (and plasma abeta 40 and 42 & p-tau-181p) on the Fujirebio Lumipulse platform; Quanterix HD-X platform multiplex assays for 1) NfL and GFAP; 2) Tau, NfL, UCH-L1, GFAP; and 3) Abeta40, Abeta42, GFAP, NfL
- Duke Brain Imaging and Analysis Center
- UNC Biomedical Research Imaging Center
- Duke Molecular Physiology Institute
Weili Lin, PhD
Dixie Lee Boney Soo Distinguished Professor of Neurological Medicine, UNC
Allen Song, PhD
Professor in Radiology, Duke University
Junior Associate Core Leader
Miles Berger, MD, PhD
Associate Professor or Anesthesiology, Duke University
- Clinical Research Specialists (TBD)